Nuvalent (NASDAQ:NUVL) Earns Overweight Rating from Analysts at Wells Fargo & Company

Equities researchers at Wells Fargo & Company initiated coverage on shares of Nuvalent (NASDAQ:NUVL) in a report released on Monday. The brokerage set an “overweight” rating and a $116.00 price target on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 20.01% from the company’s current price.

NUVL has been the subject of a number of other research reports. UBS Group reiterated a “buy” rating on shares of Nuvalent in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvalent in a research note on Thursday, January 22nd. Cantor Fitzgerald raised their price objective on shares of Nuvalent from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Friday, February 27th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $137.25.

Nuvalent Stock Performance

Shares of NUVL opened at $96.66 on Monday. The business has a 50-day moving average of $101.87 and a 200 day moving average of $98.42. Nuvalent has a fifty-two week low of $55.53 and a fifty-two week high of $113.01. The firm has a market cap of $7.60 billion, a P/E ratio of -16.52 and a beta of 1.32.

Insider Transactions at Nuvalent

In other Nuvalent news, CFO Alexandra Balcom sold 3,181 shares of the firm’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $97.16, for a total value of $309,065.96. Following the completion of the transaction, the chief financial officer directly owned 81,733 shares of the company’s stock, valued at $7,941,178.28. This trade represents a 3.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Deborah Ann Miller sold 14,300 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $110.16, for a total transaction of $1,575,288.00. Following the transaction, the insider owned 59,634 shares of the company’s stock, valued at $6,569,281.44. This trade represents a 19.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 69,379 shares of company stock valued at $6,940,982. Company insiders own 10.20% of the company’s stock.

Hedge Funds Weigh In On Nuvalent

Several institutional investors have recently modified their holdings of NUVL. AQR Capital Management LLC lifted its position in shares of Nuvalent by 64.8% in the 1st quarter. AQR Capital Management LLC now owns 9,874 shares of the company’s stock worth $700,000 after purchasing an additional 3,881 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Nuvalent by 54.4% during the first quarter. Goldman Sachs Group Inc. now owns 453,620 shares of the company’s stock valued at $32,171,000 after buying an additional 159,873 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Nuvalent by 8.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company’s stock worth $10,634,000 after buying an additional 12,123 shares in the last quarter. Intech Investment Management LLC raised its stake in Nuvalent by 28.7% in the first quarter. Intech Investment Management LLC now owns 19,262 shares of the company’s stock worth $1,366,000 after buying an additional 4,293 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in Nuvalent by 8.4% in the second quarter. Swiss National Bank now owns 75,800 shares of the company’s stock worth $5,784,000 after buying an additional 5,900 shares during the period. 97.26% of the stock is currently owned by institutional investors.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.